• BridgeBio Pharma recently reported positive topline results from PROPEL 3, its global Phase 3 trial of oral infigratinib in children with achondroplasia, showing statistically significant gains in annualized height velocity, improved body proportionality in younger children, and a favorable tolerability profile with no serious drug-related adverse events.
• An interesting aspect of the data is that infigratinib delivered the highest absolute annualized height velocity and height Z-score improvement yet reported in a randomized achondroplasia trial, and BridgeBio now plans to seek US and European approvals in the second half of 2026 while expanding studies into hypochondroplasia and infants.
• We’ll now examine how infigratinib’s Phase 3 success and planned regulatory filings could reshape BridgeBio’s late-stage genetic disease investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

BridgeBio Pharma Investment Narrative Recap

To own BridgeBio today, you need to believe its late-stage genetic disease pipeline can eventually rebalance the business away from heavy reliance on Attruby, despite ongoing losses and high R&D spend. The infigratinib Phase 3 win meaningfully strengthens that pipeline and adds a fresh potential regulatory catalyst in the second half of 2026, but it does not remove the near term risk that trial setbacks, regulatory delays, or rising costs could still pressure cash and require dilution.

The most directly relevant recent announcement is BridgeBio’s plan to submit an NDA for encaleret in the first half of 2026, adding another potential near-term approval alongside future infigratinib filings. Together, these late-stage programs could diversify revenue beyond ATTR-CM if they reach the market, which matters for investors watching both the growing competition in ATTR-CM and the company’s ongoing high operating expenses relative to current sales.

Yet investors should be aware that the biggest risk may be how long BridgeBio can fund this broad pipeline before...

BridgeBio Pharma's narrative projects $1.7 billion revenue and $297.7 million earnings by 2028.

Uncover how BridgeBio Pharma's forecasts yield a $89.79 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$2.3 billion by 2028, with earnings of roughly US$530 million, while also warning that rising operating costs might outpace revenue. If you are weighing today’s infigratinib data against that kind of upside scenario, it is worth remembering that such forecasts are far more optimistic than consensus and may be revised as the full implications of the PROPEL 3 results become clearer.

Explore 8 other fair value estimates on BridgeBio Pharma - why the stock might be worth less than half the current price!

Build Your Own BridgeBio Pharma Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your BridgeBio Pharma research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free BridgeBio Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate BridgeBio Pharma's overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.